rozanolixizumab   Click here for help

GtoPdb Ligand ID: 9801

Synonyms: CA170_01519.g57 IgG4P | UCB-7665 | UCB7665
Immunopharmacology Ligand
Compound class: Antibody
Comment: Rozanolixizumab is an anti-human FcRn monoclonal antibody that is being developed for potential use in the treatment of IgG-driven autoimmune diseases [1-2].
Click here for help
No information available.
Summary of Clinical Use Click here for help
Rozanolixizumab (as research code UCB7665) has progressed to Phase 2 clinical trial in patients with myasthenia gravis (NCT03052751) and primary immune thrombocytopenia (NCT02718716).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02718716 Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia Phase 2 Interventional UCB Pharma
NCT03052751 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Phase 2 Interventional UCB Pharma